Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710

Abramson Cancer Center at Penn Medicine

Status: Completed

Conditions: Bladder Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT02756637

UPCC 15816

Details and patient eligibility

About

The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after curative treatment for BC and 2) that baseline NLR is correlated with the survival benefit of NAC. The study will look at the data from participants of the SWOG 8710 study.

Enrollment: 634 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. SWOG 8710 original trial inclusion criteria included:

   • Node-negative, muscle-invasive transitional cell carcinoma of the bladder, T2-T4aN0M0 per the AJCC 4th edition staging manual.
   • SWOG performance status of 0 or 1
   • Adequate organ function by lab criteria (WBC > 4,000 cells/mm3, platelets >150,000 cells/mm3, creatinine <1.5 md/dL (men) or <1.3 md/dL (women), baseline liver tests < 2 times normal limits)

2. Inclusion criteria for this secondary analysis are:

   • Eligible for original SWOG 8710 trial
   • Had complete blood count with differential prior to first treatment (radical cystectomy or NAC).

Exclusion criteria

1. SWOG 8710 original trial exclusion criteria included:

   • No age restrictions
   • Previous or concomitant malignancy other than bladder cancer or basal cell skin cancer
   • Prior pelvic radiation
   • Metastatic or incurable disease
   • Laboratory values exceeding those detailed in 3.1.c

2. Exclusion criteria for this secondary analysis are:

   • Ineligibility for the original SWOG 8710 study
   • Lack of complete blood count with differential prior to first treatment (cystectomy or NAC).

Trial design

634 participants in 2 patient groups

Prognostic

Description:

Patients with NLR who completed curative therapy (surgery with or without chemo)

Predictive

Description:

Patients with NLR who were assigned to a trial arm (chemo or no chemo)